Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer

Motomu Tanaka, Hiroya Takeuchi, Yoshiki Osaki, Kunihiko Hiraiwa, Rieko Nakamura, Takashi Oyama, Tsunehiro Takahashi, Norihito Wada, Hirofumi Kawakubo, Yoshiro Saikawa, Tai Omori, Yuukou Kitagawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: The purpose of this study was to establish the clinicopathological significance of circulating tumor cells (CTCs) in patients with advanced or recurrent esophageal cancer who received either chemotherapy or chemoradiotherapy.

Methods: CTCs from 38 patients with advanced or recurrent esophageal cancer were quantified using the CellSearch system before and approximately 3–5 weeks after the initiation of a new line of chemotherapy or chemoradiotherapy. The correlation between CTC counts and clinicopathological variables was examined.

Results: Of the 38 patients, 15 (39 %) had recurrent esophageal cancer, and 23 patients (61 %) had primary advanced esophageal cancer. The mean age was 63 years (range 43–87 years). One patient (2.6 %) had a complete response to treatment, 16 (42.1 %) had a partial response, 12 (31.6 %) showed stable disease, and nine (23.7 %) showed signs of progressive disease. The overall survival of patients with ≥2 CTCs was significantly shorter than that of patients with <2 CTCs both at baseline and at first follow-up (p = 0.047 and p = 0.011, respectively). Significant correlation was found between the change in CTC counts and the response to treatment (p = 0.036). The overall survival in patients with ≥2 CTCs both at baseline and at first follow-up was significantly shorter than patients with <2 CTCs both at baseline and at first follow-up (p = 0.002). Patients with a reduction rate in the CTC value <80 % experienced significantly shorter survival than patients with a reduction rate of ≥80 % (p = 0.035). The CTC counts at first follow-up served as an independent prognostic factor (p = 0.011).

Conclusions: Our results suggest that measuring the number of CTCs in patients with advanced or recurrent esophageal cancer can be useful for predicting the survival of patients and for monitoring the response to cancer treatments.

Original languageEnglish
JournalEsophagus
DOIs
Publication statusAccepted/In press - 2014 Dec 30

Fingerprint

Circulating Neoplastic Cells
Esophageal Neoplasms
Survival
Cell Count
Chemoradiotherapy
Drug Therapy
Physiologic Monitoring

Keywords

  • CellSearch system
  • Circulating tumor cells
  • Esophageal cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer. / Tanaka, Motomu; Takeuchi, Hiroya; Osaki, Yoshiki; Hiraiwa, Kunihiko; Nakamura, Rieko; Oyama, Takashi; Takahashi, Tsunehiro; Wada, Norihito; Kawakubo, Hirofumi; Saikawa, Yoshiro; Omori, Tai; Kitagawa, Yuukou.

In: Esophagus, 30.12.2014.

Research output: Contribution to journalArticle

Tanaka, Motomu ; Takeuchi, Hiroya ; Osaki, Yoshiki ; Hiraiwa, Kunihiko ; Nakamura, Rieko ; Oyama, Takashi ; Takahashi, Tsunehiro ; Wada, Norihito ; Kawakubo, Hirofumi ; Saikawa, Yoshiro ; Omori, Tai ; Kitagawa, Yuukou. / Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer. In: Esophagus. 2014.
@article{f337ed0bc4544cc5b7d18097beeb88fc,
title = "Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer",
abstract = "Introduction: The purpose of this study was to establish the clinicopathological significance of circulating tumor cells (CTCs) in patients with advanced or recurrent esophageal cancer who received either chemotherapy or chemoradiotherapy.Methods: CTCs from 38 patients with advanced or recurrent esophageal cancer were quantified using the CellSearch system before and approximately 3–5 weeks after the initiation of a new line of chemotherapy or chemoradiotherapy. The correlation between CTC counts and clinicopathological variables was examined.Results: Of the 38 patients, 15 (39 {\%}) had recurrent esophageal cancer, and 23 patients (61 {\%}) had primary advanced esophageal cancer. The mean age was 63 years (range 43–87 years). One patient (2.6 {\%}) had a complete response to treatment, 16 (42.1 {\%}) had a partial response, 12 (31.6 {\%}) showed stable disease, and nine (23.7 {\%}) showed signs of progressive disease. The overall survival of patients with ≥2 CTCs was significantly shorter than that of patients with <2 CTCs both at baseline and at first follow-up (p = 0.047 and p = 0.011, respectively). Significant correlation was found between the change in CTC counts and the response to treatment (p = 0.036). The overall survival in patients with ≥2 CTCs both at baseline and at first follow-up was significantly shorter than patients with <2 CTCs both at baseline and at first follow-up (p = 0.002). Patients with a reduction rate in the CTC value <80 {\%} experienced significantly shorter survival than patients with a reduction rate of ≥80 {\%} (p = 0.035). The CTC counts at first follow-up served as an independent prognostic factor (p = 0.011).Conclusions: Our results suggest that measuring the number of CTCs in patients with advanced or recurrent esophageal cancer can be useful for predicting the survival of patients and for monitoring the response to cancer treatments.",
keywords = "CellSearch system, Circulating tumor cells, Esophageal cancer",
author = "Motomu Tanaka and Hiroya Takeuchi and Yoshiki Osaki and Kunihiko Hiraiwa and Rieko Nakamura and Takashi Oyama and Tsunehiro Takahashi and Norihito Wada and Hirofumi Kawakubo and Yoshiro Saikawa and Tai Omori and Yuukou Kitagawa",
year = "2014",
month = "12",
day = "30",
doi = "10.1007/s10388-014-0482-0",
language = "English",
journal = "Esophagus",
issn = "1612-9059",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer

AU - Tanaka, Motomu

AU - Takeuchi, Hiroya

AU - Osaki, Yoshiki

AU - Hiraiwa, Kunihiko

AU - Nakamura, Rieko

AU - Oyama, Takashi

AU - Takahashi, Tsunehiro

AU - Wada, Norihito

AU - Kawakubo, Hirofumi

AU - Saikawa, Yoshiro

AU - Omori, Tai

AU - Kitagawa, Yuukou

PY - 2014/12/30

Y1 - 2014/12/30

N2 - Introduction: The purpose of this study was to establish the clinicopathological significance of circulating tumor cells (CTCs) in patients with advanced or recurrent esophageal cancer who received either chemotherapy or chemoradiotherapy.Methods: CTCs from 38 patients with advanced or recurrent esophageal cancer were quantified using the CellSearch system before and approximately 3–5 weeks after the initiation of a new line of chemotherapy or chemoradiotherapy. The correlation between CTC counts and clinicopathological variables was examined.Results: Of the 38 patients, 15 (39 %) had recurrent esophageal cancer, and 23 patients (61 %) had primary advanced esophageal cancer. The mean age was 63 years (range 43–87 years). One patient (2.6 %) had a complete response to treatment, 16 (42.1 %) had a partial response, 12 (31.6 %) showed stable disease, and nine (23.7 %) showed signs of progressive disease. The overall survival of patients with ≥2 CTCs was significantly shorter than that of patients with <2 CTCs both at baseline and at first follow-up (p = 0.047 and p = 0.011, respectively). Significant correlation was found between the change in CTC counts and the response to treatment (p = 0.036). The overall survival in patients with ≥2 CTCs both at baseline and at first follow-up was significantly shorter than patients with <2 CTCs both at baseline and at first follow-up (p = 0.002). Patients with a reduction rate in the CTC value <80 % experienced significantly shorter survival than patients with a reduction rate of ≥80 % (p = 0.035). The CTC counts at first follow-up served as an independent prognostic factor (p = 0.011).Conclusions: Our results suggest that measuring the number of CTCs in patients with advanced or recurrent esophageal cancer can be useful for predicting the survival of patients and for monitoring the response to cancer treatments.

AB - Introduction: The purpose of this study was to establish the clinicopathological significance of circulating tumor cells (CTCs) in patients with advanced or recurrent esophageal cancer who received either chemotherapy or chemoradiotherapy.Methods: CTCs from 38 patients with advanced or recurrent esophageal cancer were quantified using the CellSearch system before and approximately 3–5 weeks after the initiation of a new line of chemotherapy or chemoradiotherapy. The correlation between CTC counts and clinicopathological variables was examined.Results: Of the 38 patients, 15 (39 %) had recurrent esophageal cancer, and 23 patients (61 %) had primary advanced esophageal cancer. The mean age was 63 years (range 43–87 years). One patient (2.6 %) had a complete response to treatment, 16 (42.1 %) had a partial response, 12 (31.6 %) showed stable disease, and nine (23.7 %) showed signs of progressive disease. The overall survival of patients with ≥2 CTCs was significantly shorter than that of patients with <2 CTCs both at baseline and at first follow-up (p = 0.047 and p = 0.011, respectively). Significant correlation was found between the change in CTC counts and the response to treatment (p = 0.036). The overall survival in patients with ≥2 CTCs both at baseline and at first follow-up was significantly shorter than patients with <2 CTCs both at baseline and at first follow-up (p = 0.002). Patients with a reduction rate in the CTC value <80 % experienced significantly shorter survival than patients with a reduction rate of ≥80 % (p = 0.035). The CTC counts at first follow-up served as an independent prognostic factor (p = 0.011).Conclusions: Our results suggest that measuring the number of CTCs in patients with advanced or recurrent esophageal cancer can be useful for predicting the survival of patients and for monitoring the response to cancer treatments.

KW - CellSearch system

KW - Circulating tumor cells

KW - Esophageal cancer

UR - http://www.scopus.com/inward/record.url?scp=84920110613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920110613&partnerID=8YFLogxK

U2 - 10.1007/s10388-014-0482-0

DO - 10.1007/s10388-014-0482-0

M3 - Article

JO - Esophagus

JF - Esophagus

SN - 1612-9059

ER -